The Biotech Industry Finally Turns a Profit

They say that nobody should start a company to make money. Here’s proof: for all the buzz about biotech, in 40 years (really, 42, since Genentech’s founding in 1976), the biotech industry as a whole never made a profit — until last year. Drawing on data from publicly-traded companies, Peter Winter, editor at the biotech merchant bank Burrill & Co., put together a report that found biotech as an industry made money in 2008, about $9.4 billion in net profits.

That might seem like bright sign for biotech, given what a bad year 2008 was for so many industrial sectors. But, as Winter tells us in this podcast, biotech in the black, 2009 could be much worse. After all, only 67 biotech companies were actually profitable in 2008. Worse, almost all the profits, about $8 billion, went to three companies: Genentech, Amgen and Gilead.

Winter says that the 298 companies in biotech lost a combined $6 billion (these are, of course, just the publicly traded firms). He expects a very challenging next 12 to 18 months for the capital-hungry biotech sector. He thinks as many as 200 biotech firms are in trouble, and perhaps one-third of all biotech firms will disappear, through acquisition, merger or just plain death.

“The industry will be totally different 12 months from now,” Winter says.

One promising thing for those starting out now: the Big Three of biotech all got going during tough times — Genentech in 1976, just after the vicious 1973-75 recession, Amgen in 1980, as America dipped in and out of recession, and Gilead in 1987, the year of a major market crash. When Genentech started, almost nobody believed in biotech. If nobody believes in you now, maybe in 40 years you’ll be looking at an entire industry that’s finally making money.

This post first appeared in BNET’s Big Think blog.